Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy

Pediatric Infectious Disease Journal

Volumn 25, Issue 11, 2006, Pages 1049-1056

  Averbuch, Diana ^a   Schapiro, Jonathan M ^b   Lanier, E Randall ^c   Gradstein, Serge ^d   Gottesman, Giora ^e   Kedem, Eynat ^f   Einhorn, Menachem ^g   Grisaru Soen, Galia ^h   Ofir, Michal ⁱ   Engelhard, Dan ^a   Grossman, Zehava ^b,j  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c GLAXOSMITHKLINE   (United States)

^d KAPLAN MEDICAL CENTER   (Israel)

^e MEIR MEDICAL CENTER   (Israel)

^f RAMBAM MEDICAL CENTER   (Israel)

^g BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^h TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

ⁱ Visible Genetics Inc   (Israel)

^j MOH   (Israel)

more..

Author keywords

African children; M184V; NRTI; Phenotype and genotype resistance testing; Subtype C HIV I infected children; Thymidine analog mutations (TAMs)

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; THYMIDINE; VIRUS RNA; ZALCITABINE;

ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CHILD; CONTROLLED STUDY; DRUG SENSITIVITY; ETHIOPIA; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; MUTATION; PRIORITY JOURNAL; VIRUS LOAD; VIRUS REPLICATION;

ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INFANT; INHIBITORY CONCENTRATION 50; LAMIVUDINE; MALE; MICROBIAL SENSITIVITY TESTS; MUTATION; PHENOTYPE; REVERSE TRANSCRIPTASE INHIBITORS; SELECTION (GENETICS); THYMIDINE; VIRUS REPLICATION; ZIDOVUDINE;

EID: 33750433935     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000243211.36690.d5     Document Type: Article

References (37)

1. UNAIDS Report. UNAIDS; 2004.
2. Ariyoshi K, Matsuda M, Miura H, Tateishi S, Yamada K, Sugiura W. Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection. J Acquir Immune Defic Syndr. 2003;33:336-342.
3. Brenner BG, Routy JP, Petrella M, et al. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol. 2002;76:1753-1761.
4. Cane PA, de Ruiter A, Rice P, Wiselka M, Fox R, Pillay D. Resistance-associated mutations in the human immunodeficiency virus type 1 subtype c protease gene from treated and untreated patients in the United Kingdom. J Clin Microbiol. 2001;39:2652-2654.
5. Gomes P, Diogo I, Goncalves MF, et al. Different Pathways to Nelfinavir Genotypic Resistance in HIV-1 Subtypes B and G. 9th Conference on Retroviruses and Opportunistic Infections; Seattle, WA; 2002:Abstract 46.
6. Grossman Z, Vardinon N, Chemtob D, et al. Genotypic variation of HIV-1 reverse transcriptase and protease: Comparative analysis of clade C and clade B. AIDS. 2001;15:1453-1460.
7. Weidle PJ, Downing R, Sozi C, et al. Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV Drug Access Initiative - Uganda. AIDS. 2003;17(suppl 3):S39-48.
8. Kantor R, Zijenah LS, Shafer RW, et al. HIV-1 subtype C reverse transcriptase and protease genotypes in Zimbabwean patients failing antiretroviral therapy. AIDS Res Hum Retroviruses. 2002;18:1407-1413.
9. Kantor R, Katzenstein DA, Efron B, et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. PLoS Med. 2005;2:e112.
10. Grossman Z, Paxinos EE, Averbuch D, et al. Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir. Antimicrob Agents Chemother. 2004;48:2159-2165.
11. Grossman Z, Istomin V, Averbuch D, et al. Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C. AIDS. 2004;18:909-915.
12. Grossman Z, Alkan ML, Bentwich Z, et al. Patterns of Drug Resistance: Do We Need to Adjust Treatment to Clade? 8th Conference on Retroviruses and Opportunistic Infections; Chicago, IL; 2001:Abstract No. 456.
13. Kantor R, Machekano R, Gonzales MJ, Dupnik K, Schapiro JM, Shafer RW. Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database: an expanded data model integrating natural language text and sequence analysis programs. Nucleic Acids Res. 2001;29:296-299.
14. Wu TD, Schiffer CA, Gonzales MJ, et al. Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J Virol. 2003;77:4836-4847.
15. Petropoulos CJ, Parkin NT, Limoli KL, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2000;44:920-928.
16. Brenner BG, Oliveira M, Doualla-Bell F, et al. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS. 2006;20:F9-13.
17. Ait-Khaled M, Stone C, Amphlett G, et al. M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine. AIDS. 2002;16:1686-1689.
18. Ait-Khaled M, Rakik A, Griffin P, et al. Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy. Antiviral Ther. 2002;7:43-51.
19. Ait-Khaled M, Rakik A, Griffin P, et al. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/ amprenavir in the CNA2007 study. Antiviral Ther. 2003;8:111-120.
20. Zaccarelli M, Perno CF, Forbici F, et al. Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation. Antiviral Ther. 2003;8: 51-56.
21. Schuurman R, Nijhuis M, van Leeuwen R, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis. 1995;171:1411-1419.
22. Gotte M, Arion D, Parniak MA, Wainberg MA. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J Virol. 2000;74: 3579-3585.
23. Meyer PR, Matsuura SE, So AG, Scott WA. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc Natl Acad Sci U S A. 1998;95:13471-13476.
24. Meyer PR, Matsuura SE, Mian AM, So AG, Scott WA. A mechanism of AZT resistance: An increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol Cell. 1999;4:35-43.
25. Boucher CA, Cammack N, Schipper P, et al. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 1993;37:2231-2234.
26. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A. 1993;90:5653-5656.
27. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science. 1995; 269:696-699.
28. Deeks SG, Barbour JD, Martin JN, Swanson MS, Grant RM. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis. 2000;181:946-953.
29. Nicastri E, Sarmati L, d'Ettorre G, et al. High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis. J Clin Microbiol. 2003;41:3007-3012.
30. Ross L, Parkin N, Chappey C, et al. Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance. AIDS. 2004;18:1691-1696.
31. Grossman Z, Lorber M, Maayan S, et al. Drug-resistant HIV infection among drug-naive patients in Israel. Clin Infect Dis. 2005;40:294-302.
32. Winters MA, Bosch RJ, Albrecht MA, Katzenstein DA. Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patients. J Infect Dis. 2003;188:537-540.
33. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. DHHS; November 3, 2005.
34. Quan Y, Brenner BG, Oliveira M, Wainberg MA. Lamivudine can exert a modest antiviral effect against human immunodeficiency virus type 1 containing the M184V mutation. Antimicrob Agents Chemother. 2003;47:747-754.
35. Castagna A, Danise A, Menzo S, et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: A randomized pilot study (E-184V study). AIDS. 2006;20:795-803.
36. Turner D, Brenner BG, Routy JP, Petrella M, Wainberg MA. Rationale for maintenance of the M184v resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients. New Microbiol. 2004;27:31-39.
37. Wainberg MA. The impact of the M184V substitution on drug resistance and viral fitness. Exp Rev Anti Infect Ther. 2004;2:147-151.